An innovative way to treat cGVHD1-3
Belumosudil (REZUROCK®) has been added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a category 2A systemic option for steroid-refractory cGVHD.4,a
The ORRb,c was 75% at the recommended dose of 200 mg once daily (n=65) in the pivotal ROCKstar study.
EXPLORE EFFICACYREZUROCK was evaluated in a real-world population of patients with cGVHD.
aNCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
bBased on a final analysis by the FDA (n=65).
cProportion of patients who achieved CR or PR according to the 2014 NIH cGVHD Consensus Criteria.1
aNCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
bBased on a final analysis by the FDA (n=65).
cProportion of patients who achieved CR or PR according to the 2014 NIH cGVHD Consensus Criteria.1
A ROCK2 inhibitor designed to address the
associated with cGVHD1-3
cGVHD, chronic graft-versus-host disease; FDA, US Food and Drug Administration; MOA, mechanism of action; NCCN, National Comprehensive Cancer Network®; ORR, overall response rate; ROCK2, rho-associated coiled-coil—containing protein kinase-2.
References: 1. REZUROCK. Package insert. Kadmon Pharmaceuticals, LLC; 2023. 2. Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci USA. 2014;111(47):16814-16819. doi:10.1073/pnas.1414189111 3. Flynn R, Paz K, Du J, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016;127(17):2144-2154. doi:10.1182/blood-2015-10-678706 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Cell Transplantation (HCT). V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 19, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org